GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sol-Gel Technologies Ltd (NAS:SLGL) » Definitions » DeferredTaxAndRevenue

SLGL (Sol-Gel Technologies) DeferredTaxAndRevenue : $0.00 Mil (As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Sol-Gel Technologies DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Sol-Gel Technologies's current deferred tax and revenue for the quarter that ended in Mar. 2025 was $0.00 Mil.

Sol-Gel Technologies DeferredTaxAndRevenue Historical Data

The historical data trend for Sol-Gel Technologies's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sol-Gel Technologies DeferredTaxAndRevenue Chart

Sol-Gel Technologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sol-Gel Technologies Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Sol-Gel Technologies DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of Sol-Gel Technologies's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Sol-Gel Technologies Business Description

Traded in Other Exchanges
Address
7 Golda Meir Street, Weizmann Science Park, Ness Ziona, ISR, 7403650
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.